Sol-Gel Technologies (SLGL) Profit After Tax Growth (5y) (2022 - 2026)

Sol-Gel Technologies (SLGL) Profit After Tax Growth (5y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Sol-Gel Technologies 226.64 Mn 216.50 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 48.73%
Dec 31, 2025 43.55%
Sep 30, 2025 -7.17%
Jun 30, 2025 3,171.10%
Mar 31, 2025 57.52%
Dec 31, 2024 9.05%
Sep 30, 2024 -1,481.45%
Jun 30, 2024 2,277.73%
Mar 31, 2024 50.29%
Dec 31, 2023 -2,274.99%
Sep 30, 2023 -2,597.31%
Jun 30, 2023 2,679.29%
Mar 31, 2023 1.97%
Dec 31, 2022 -2,698.13%